Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer

NCT03072160 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT03072160
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03072160 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
June 16, 2017
Completion date
November 22, 2019
Enrollment
17 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

medullary thyroid cancer (mtc)